Info Type

FDA Approves Keytruda® for Adult and Pediatric Patients with Classical Hodgkin (March 29, 2017)

It was announced today that the U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric... Continue Reading

Colon Cancer Surgery: Minimally Invasive Laparoscopic Surgery versus Open Colectomy (March 28, 2017)

If you’ve been diagnosed with colon cancer and your healthcare team has determined that you’re a candidate for either complete or partial removal of your colon (colectomy) or a minimally invasive surgical... Continue Reading

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant (March 28, 2017)

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous... Continue Reading

Strategies to Help Get Your Thinking Back on Track (March 28, 2017)

The recorded version of the webchat will be available here as soon as possible.   Cancer often causes changes in memory, word retrieval, planning, organization, and the ability to multi-task. These... Continue Reading

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (March 23, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy... Continue Reading

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma (March 22, 2017)

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival... Continue Reading

March is Multiple Myeloma Awareness Month: Learn About Recent Advances (March 21, 2017)

There are several recent advances of note in the management of all stages of Multiple Myeloma. Smoldering myeloma is considered to be a pre-cancerous condition, in which patients do not yet display any... Continue Reading

Lynparza Improves Progression-Free Survival in BRCA-Mutated Ovarian Cancer (March 21, 2017)

Results were recently presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in National Harbor, USA, demonstrating that Lynparza (olaparib) reduced the risk of platinum-sensitive,... Continue Reading

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when... Continue Reading

Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation (March 16, 2017)

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option.  However, a technique that limits the application... Continue Reading

Newly Diagnosed with Ovarian Cancer? 10 Must Read Empowered Patient Tips (March 15, 2017)

For many years ovarian cancer has been referred to as “the silent killer” due to its vague, ignored, or misdiagnosed symp­toms. Because of this and the lack of ear­ly-detection tools, ovarian cancer... Continue Reading

telotristat ethyl (March 15, 2017)

Class: Supportive Care Generic Name: telotristat ethyl Trade Name: Xermelo™ For which conditions is this drug approved? Telotristat ethyl is approved to be used in combination with somatostatin analog... Continue Reading

Xermelo™ (March 15, 2017)

Class: Supportive Care Generic Name: telotristat ethyl Trade Name: Xermelo™ For which conditions is this drug approved? Telotristat ethyl is approved to be used in combination with somatostatin analog... Continue Reading

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma (March 15, 2017)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm... Continue Reading

Patients With NSCLC Are Not Undergoing Biomarker Testing for Precision Medicines-Patient Education is Key (March 14, 2017)

Despite guidelines recommending testing, patients with stage IV non-small cell lung cancer (NSCLC) who are treated in the community setting are undergoing EGFR/ALK biomarker testing.1 Doctors are currently... Continue Reading

Know Your Treatment Options: Colorectal Cancer Liver Metastases (March 13, 2017)

Nearly 136,000 Americans are expected to be diagnosed with colorectal (CRC) cancer this year,1 and more than 50% will have their cancer spread to their liver.2  Many individuals with CRC involving the... Continue Reading

Genetic Factors and Colorectal Cancer: Know Your Risk (March 10, 2017)

Colorectal cancer is one of several cancers with known genetic risk factors. Because these known factors can be identified through genetic testing, it’s important to understand your risks and to discuss... Continue Reading

Upcoming Educational Forum for Waldenstrom’s Macroglobulinemia Patients and Caregivers (March 9, 2017)

The 22nd Annual IWMF Educational Forum May 19-21, 2017, in Phoenix, Arizona The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-led, nonprofit organization... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS